Enanta Pharmaceuticals (ENTA) Receivables - Net (2012 - 2026)

Enanta Pharmaceuticals has reported Receivables - Net for 15 years, with the latest figure at $7.8 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net rose 14.97% year-over-year to $7.8 million; the trailing twelve-month figure through Mar 2026 stood at $7.8 million (up 14.97% YoY), and the FY2025 full-year result was $6.9 million, up 3.55% from the prior year.
• Receivables - Net for Q1 2026 stood at $7.8 million, down from $8.5 million in the prior quarter.
• The five-year high for Receivables - Net was $22.6 million in Q4 2022, with the low at $6.6 million in Q3 2024.
• Historically, Receivables - Net has averaged $12.0 million across 5 years, with a median of $8.3 million in 2025.
• Annual changes were most pronounced in 2023 — Receivables - Net slumped 63.81% — and 2026, when it gained 14.97%.
• Enanta Pharmaceuticals' Receivables - Net stood at $22.6 million in 2022, then tumbled by 63.81% to $8.2 million in 2023, then dropped by 5.57% to $7.7 million in 2024, then rose by 10.04% to $8.5 million in 2025, then retreated by 8.05% to $7.8 million in 2026.
• The last three Receivables - Net figures came in at $7.8 million (Q1 2026), $8.5 million (Q4 2025), and $6.9 million (Q3 2025), per Business Quant data.